PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Steroids - Market size and forecast 2018-2023 Antibiotics - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DRIVERS AND CHALLENGES Market drivers Market challenges PART 10: MARKET TRENDS PART 11: VENDOR LANDSCAPE Overview Landscape disruption PART 12: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Akorn Inc. Allergan Plc Bausch Health Companies Inc. Novartis AG Pfizer Inc. PART 13: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 14: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Steroids - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Steroids - Year-over-year growth 2019-2023 (%) Exhibit 22: Antibiotics - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Antibiotics - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by product Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Some of the combination drugs available in the market Exhibit 43: Impact of drivers and challenges Exhibit 44: Recent strategic alliances in ophthalmology: Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Akorn Inc. - Vendor overview Exhibit 51: Akorn Inc. - Business segments Exhibit 52: Akorn Inc. - Organizational developments Exhibit 53: Akorn Inc. - Segment focus Exhibit 54: Akorn Inc. - Key offerings Exhibit 55: Akorn Inc. - Key customers Exhibit 56: Allergan Plc - Vendor overview Exhibit 57: Allergan Plc - Product segments Exhibit 58: Allergan Plc - Organizational developments Exhibit 59: Allergan Plc - Geographic focus Exhibit 60: Allergan Plc - Segment focus Exhibit 61: Allergan Plc - Key offerings Exhibit 62: Allergan Plc - Key customers Exhibit 63: Bausch Health Companies Inc. - Vendor overview Exhibit 64: Bausch Health Companies Inc. - Business segments Exhibit 65: Bausch Health Companies Inc. - Organizational developments Exhibit 66: Bausch Health Companies Inc. - Geographic focus Exhibit 67: Bausch Health Companies Inc. - Segment focus Exhibit 68: Bausch Health Companies Inc. - Key offerings Exhibit 69: Bausch Health Companies Inc. - Key customers Exhibit 70: Novartis AG - Vendor overview Exhibit 71: Novartis AG - Business segments Exhibit 72: Novartis AG - Organizational developments Exhibit 73: Novartis AG - Geographic focus Exhibit 74: Novartis AG - Segment focus Exhibit 75: Novartis AG - Key offerings Exhibit 76: Novartis AG - Key customers Exhibit 77: Pfizer Inc. - Vendor overview Exhibit 78: Pfizer Inc. - Business segments Exhibit 79: Pfizer Inc. - Organizational developments Exhibit 80: Pfizer Inc. - Geographic focus Exhibit 81: Pfizer Inc. - Segment focus Exhibit 82: Pfizer Inc. - Key offerings Exhibit 83: Pfizer Inc. - Key customers Exhibit 84: Validation techniques employed for market sizing Exhibit 85: Definition of market positioning of vendors

Akorn Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.